Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of furmonertinib in EGFR-mutant NSCLC with brain or leptomeningeal metastases
ChiCTR2300071395Phase 2Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Central nervous system progression-free survival. Planned start May 2023; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300071395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071395.